ArticleInternational journal of rheumatic diseases2025
Canakinumab Treatment in Familial Mediterranean Fever Patients: With/Without Colchicine.
Article in International journal of rheumatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the differences in attack characteristics, acute-phase reactants, and renal outcomes in patients using canakinumab with or without colchicine treatment.
methodsFMF patients treated with canakinumab for ≥ 3 months were retrospectively reviewed. Patients unable to continue colchicine for various reasons were identified and grouped as those receiving the canakinumab + colchicine combination (CAN + CLC) and canakinumab monotherapy (CANmono). Attack frequency, C-reactive protein (CRP), urine protein-creatinine ratio (UPCR), and kidney function tests were recorded before and after canakinumab treatment.
resultsFifty-five patients receiving canakinumab treatment were included in the study. Thirty-one patients (56.4%) used CAN + CLC and 24 (43.6%) CANmono. With both CAN + CLC and CANmono treatment, there was no significant change in UPCR of patient groups with GFR > 60 and < 60 mL/min/1.73 m
conclusionIt is difficult to make a recommendation regarding the discontinuation or continuation of colchicine treatment in all FMF patients who initiated anti-IL-1 treatment. Canakinumab can be continued as monotherapy in patients who cannot continue colchicine treatment due to side effects and patient noncompliance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.